BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Siafis S, Çıray O, Schneider-Thoma J, Bighelli I, Krause M, Rodolico A, Ceraso A, Deste G, Huhn M, Fraguas D, Mavridis D, Charman T, Murphy DG, Parellada M, Arango C, Leucht S. Placebo response in pharmacological and dietary supplement trials of autism spectrum disorder (ASD): systematic review and meta-regression analysis. Mol Autism 2020;11:66. [PMID: 32847616 DOI: 10.1186/s13229-020-00372-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Trembath D, Varcin K, Waddington H, Sulek R, Bent C, Ashburner J, Eapen V, Goodall E, Hudry K, Roberts J, Silove N, Whitehouse A. Non-pharmacological interventions for autistic children: An umbrella review. Autism 2022;:13623613221119368. [PMID: 36081343 DOI: 10.1177/13623613221119368] [Reference Citation Analysis]
2 Mason L, Moessnang C, Chatham C, Ham L, Tillmann J, Dumas G, Ellis C, Leblond CS, Cliquet F, Bourgeron T, Beckmann C, Charman T, Oakley B, Banaschewski T, Meyer-Lindenberg A, Baron-Cohen S, Bölte S, Buitelaar JK, Durston S, Loth E, Oranje B, Persico A, Dell'Acqua F, Ecker C, Johnson MH, Murphy D, Jones EJH. Stratifying the autistic phenotype using electrophysiological indices of social perception. Sci Transl Med 2022;14:eabf8987. [PMID: 35976994 DOI: 10.1126/scitranslmed.abf8987] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Hollander E, Jacob S, Jou R, Mcnamara N, Sikich L, Tobe R, Smith J, Sanders K, Squassante L, Murtagh L, Gleissl T, Wandel C, Veenstra-vanderweele J. Balovaptan vs Placebo for Social Communication in Childhood Autism Spectrum Disorder: A Randomized Clinical Trial. JAMA Psychiatry. [DOI: 10.1001/jamapsychiatry.2022.1717] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Jacob S, Anagnostou E, Hollander E, Jou R, McNamara N, Sikich L, Tobe R, Murphy D, McCracken J, Ashford E, Chatham C, Clinch S, Smith J, Sanders K, Murtagh L, Noeldeke J, Veenstra-VanderWeele J. Large multicenter randomized trials in autism: key insights gained from the balovaptan clinical development program. Mol Autism 2022;13:25. [PMID: 35690870 DOI: 10.1186/s13229-022-00505-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Salazar de Pablo G, Jordá CP, Vaquerizo-Serrano J, Moreno C, Cabras A, Arango C, Hernández P, Veenstra-VanderWeele J, Simonoff E, Fusar-Poli P, Santosh P, Cortese S, Parellada M. Systematic Review and Meta-analysis: Efficacy of Pharmacological Interventions for Irritability and Emotional Dysregulation in Autism Spectrum Disorder and Predictors of Response. J Am Acad Child Adolesc Psychiatry 2022:S0890-8567(22)00198-8. [PMID: 35470032 DOI: 10.1016/j.jaac.2022.03.033] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Baumer NT, Becker ML, Capone GT, Egan K, Fortea J, Handen BL, Head E, Hendrix JE, Litovsky RY, Strydom A, Tapia IE, Rafii MS. Conducting clinical trials in persons with Down syndrome: summary from the NIH INCLUDE Down syndrome clinical trials readiness working group. J Neurodev Disord 2022;14:22. [PMID: 35321660 DOI: 10.1186/s11689-022-09435-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Jacob S, Veenstra-vanderweele J, Murphy D, Mccracken J, Smith J, Sanders K, Meyenberg C, Wiese T, Deol-bhullar G, Wandel C, Ashford E, Anagnostou E. Efficacy and safety of balovaptan for socialisation and communication difficulties in autistic adults in North America and Europe: a phase 3, randomised, placebo-controlled trial. The Lancet Psychiatry 2022. [DOI: 10.1016/s2215-0366(21)00429-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
8 Loth E. Placebo effects and participant heterogeneity in clinical trials of autism spectrum disorder. The Lancet Psychiatry 2022. [DOI: 10.1016/s2215-0366(21)00504-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Feng X, Jiang Q, Zhang Y, Li T, Wei W, Yu J, Li W, Li J. Pediatric Tuina in children with autism spectrum disorder: a study protocol for a randomized controlled trial. Trials 2022;23. [DOI: 10.1186/s13063-022-06030-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Taylor BP, Liu J, Mowrey W, Eule E, Bolognani F, Hollander E. The Montefiore-Einstein Rigidity Scale-Revised (MERS-R): Development, administration, reliability, and validity in child and adult Autism Spectrum Disorder (ASD). J Psychiatr Res 2022;147:142-7. [PMID: 35032947 DOI: 10.1016/j.jpsychires.2021.12.055] [Reference Citation Analysis]
11 Lotufo Denucci B, Silva de Lima L, Ferreira Lima Mota I, Rocha Madureira Azevedo J, Germino Veras L, Montenegro Luzardo Bicca JV, de Miranda Santana B, Beserra Pinheiro G, Gonçalves Coelho G, Mortari MR. Current knowledge, challenges, new perspectives of the study, and treatments of Autism Spectrum Disorder. Reprod Toxicol 2021;106:82-93. [PMID: 34695561 DOI: 10.1016/j.reprotox.2021.10.010] [Reference Citation Analysis]
12 Parellada M, San José Cáceres A, Palmer M, Delorme R, Jones EJH, Parr JR, Anagnostou E, Murphy DGM, Loth E, Wang PP, Charman T, Strydom A, Arango C. A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Arbaclofen Administered for the Treatment of Social Function in Children and Adolescents With Autism Spectrum Disorders: Study Protocol for AIMS-2-TRIALS-CT1. Front Psychiatry 2021;12:701729. [PMID: 34504446 DOI: 10.3389/fpsyt.2021.701729] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
13 Siafis S, Rodolico A, Çıray O, Murphy DG, Parellada M, Arango C, Leucht S. Imputing the Number of Responders from the Mean and Standard Deviation of CGI-Improvement in Clinical Trials Investigating Medications for Autism Spectrum Disorder. Brain Sci 2021;11:908. [PMID: 34356141 DOI: 10.3390/brainsci11070908] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
14 Kriara L, Hipp J, Chatham C, Nobbs D, Slater D, Lipsmeier F, Lindemann M. Beacon-Based Remote Measurement of Social Behavior in ASD Clinical Trials: A Technical Feasibility Assessment. Sensors (Basel) 2021;21:4664. [PMID: 34300402 DOI: 10.3390/s21144664] [Reference Citation Analysis]
15 McCracken JT, Anagnostou E, Arango C, Dawson G, Farchione T, Mantua V, McPartland J, Murphy D, Pandina G, Veenstra-VanderWeele J; ISCTM/ECNP ASD Working Group. Drug development for Autism Spectrum Disorder (ASD): Progress, challenges, and future directions. Eur Neuropsychopharmacol 2021;48:3-31. [PMID: 34158222 DOI: 10.1016/j.euroneuro.2021.05.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
16 Colizzi M, Bortoletto R, Costa R, Zoccante L. Palmitoylethanolamide and Its Biobehavioral Correlates in Autism Spectrum Disorder: A Systematic Review of Human and Animal Evidence. Nutrients 2021;13:1346. [PMID: 33919499 DOI: 10.3390/nu13041346] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
17 Arango C. Drug development in ASD, an ISCTM-ECNP joint adventure. Eur Neuropsychopharmacol 2021;48:1-2. [PMID: 33832786 DOI: 10.1016/j.euroneuro.2021.03.018] [Reference Citation Analysis]
18 Díaz-Caneja CM, State MW, Hagerman RJ, Jacquemont S, Marín O, Bagni C, Umbricht D, Simonoff E, de Andrés-Trelles F, Kaale A, Pandina G, Gómez-Mancilla B, Wang PP, Cusak J, Siafis S, Leucht S, Parellada M, Loth E, Charman T, Buitelaar JK, Murphy D, Arango C. A white paper on a neurodevelopmental framework for drug discovery in autism and other neurodevelopmental disorders. Eur Neuropsychopharmacol 2021;48:49-88. [PMID: 33781629 DOI: 10.1016/j.euroneuro.2021.02.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
19 Sprengers JJ, van Andel DM, Bruining H. Dr. Sprengers et al. Reply. J Am Acad Child Adolesc Psychiatry 2021;60:938-9. [PMID: 33450401 DOI: 10.1016/j.jaac.2020.12.034] [Reference Citation Analysis]